Lates News

The report from CITIC Securities pointed out that on May 12, 2025, Trump signed an executive order called "Providing Most Favored Nation Price for Prescription Drugs to American Patients" aimed at reducing prescription drug prices in the U.S. market. In the executive order, Trump proposed that pharmaceutical companies should align their drug prices in the U.S. with the lowest prices in comparable developed countries. At the same time, Trump also proposed to increase the transparency of drug prices in the U.S. to reduce the profit margins of "middlemen" such as PBMs. We believe that the implementation of this executive order will be difficult, and the short-term impact on the industry is expected to be limited.